Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in moderate to severe atopic dermatitis with sleep disturbance
NCT04033367Phase 4Completed
- Sponsor
- Sanofi
- Start
- Aug 2019
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 4 trial of dupilumab in atopic dermatitis (AD), sponsored by Sanofi. Started Aug 2019; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04033367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04033367.